Asra Karim1, Daniela Farrugia, James Cheshire, Sophia Mahboob, Irena Begaj, Daniel Ray, Adnan Sharif. 1. 1 Department of Nephrology and Transplantation, Renal Institute of Birmingham, Queen Elizabeth Hospital, Birmingham, UK. 2 Medical School, University of Birmingham, Birmingham, UK. 3 Department of Medical Informatics, Queen Elizabeth Hospital, Birmingham, UK. 4 Address correspondence to: Adnan Sharif, M.D., Renal Institute of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2WB, UK.
Abstract
BACKGROUND: The aim of this study was to explore age-related mortality post-kidney transplantation in England over the last decade. METHODS: This study used data from Hospital Episode Statistics to select all kidney transplant procedures performed in England between April 2001 and March 2012. Demographics and medical comorbidities (based upon ICD-10 codes) were extracted at baseline. Data linkage analysis was performed with the Office for National Statistics to identify all deaths occurring among this study cohort. RESULTS: Data for 19,103 kidney transplant procedures was analyzed, with a median follow-up of 4.4 years (interquartile range 2.2-7.3 years). Categorization of age cohorts at time of transplantation were age below 50 (n=11,421, 59.8%), 50 to 59 (n=4,195, 22.0%), 60 to 69 (n=2,887, 15.1%), 70 to 79 (n=589, 3.1%), and 80 and above (n=11, 0.1%). There were 2,085 deaths that occurred among the study cohort during follow-up and mortality risk increased with age: below 50 (5.8%), 50 to 59 (14.2%), 60 to 69 (22.0%), 70 to 79 (31.9%), and 80 and above (45.5%). The three most common causes of deaths for recipients 70 and over were cardiac (21.2%), infection (21.2%), and malignancy (20.2%), respectively. Lower mortality was observed with the receipt of a living-donor kidney for recipients aged 70 and above. On Cox regression analysis, risk for death increased with each additional decade of recipient age over 50. CONCLUSION: Increasing age is a strong, independent risk factor for death after kidney transplantation. Although lower mortality was observed with living kidney transplantation among elderly recipients, living-donor rates decrease with increasing recipient age. Pretransplant counseling and posttransplant tailored immunosuppression should be explored, the latter requiring targeted clinical trials.
BACKGROUND: The aim of this study was to explore age-related mortality post-kidney transplantation in England over the last decade. METHODS: This study used data from Hospital Episode Statistics to select all kidney transplant procedures performed in England between April 2001 and March 2012. Demographics and medical comorbidities (based upon ICD-10 codes) were extracted at baseline. Data linkage analysis was performed with the Office for National Statistics to identify all deaths occurring among this study cohort. RESULTS: Data for 19,103 kidney transplant procedures was analyzed, with a median follow-up of 4.4 years (interquartile range 2.2-7.3 years). Categorization of age cohorts at time of transplantation were age below 50 (n=11,421, 59.8%), 50 to 59 (n=4,195, 22.0%), 60 to 69 (n=2,887, 15.1%), 70 to 79 (n=589, 3.1%), and 80 and above (n=11, 0.1%). There were 2,085 deaths that occurred among the study cohort during follow-up and mortality risk increased with age: below 50 (5.8%), 50 to 59 (14.2%), 60 to 69 (22.0%), 70 to 79 (31.9%), and 80 and above (45.5%). The three most common causes of deaths for recipients 70 and over were cardiac (21.2%), infection (21.2%), and malignancy (20.2%), respectively. Lower mortality was observed with the receipt of a living-donor kidney for recipients aged 70 and above. On Cox regression analysis, risk for death increased with each additional decade of recipient age over 50. CONCLUSION: Increasing age is a strong, independent risk factor for death after kidney transplantation. Although lower mortality was observed with living kidney transplantation among elderly recipients, living-donor rates decrease with increasing recipient age. Pretransplant counseling and posttransplant tailored immunosuppression should be explored, the latter requiring targeted clinical trials.
Authors: Jule Pinter; Camilla S Hanson; Jeremy R Chapman; Germaine Wong; Jonathan C Craig; Jane O Schell; Allison Tong Journal: Clin J Am Soc Nephrol Date: 2017-01-31 Impact factor: 8.237
Authors: María José Pérez-Sáez; Núria Montero; Dolores Redondo-Pachón; Marta Crespo; Julio Pascual Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Jiang-Tao Tang; Brenda C de Winter; Dennis A Hesselink; Ferdi Sombogaard; Lan-Lan Wang; Teun van Gelder Journal: Br J Clin Pharmacol Date: 2016-11-30 Impact factor: 4.335
Authors: F Krenzien; M Quante; T Heinbokel; M Seyda; K Minami; H Uehara; H R C Biefer; J M Schuitenmaker; S Gabardi; K Splith; M Schmelzle; A K Petrides; H Azuma; J Pratschke; X C Li; A ElKhal; S G Tullius Journal: Am J Transplant Date: 2016-11-21 Impact factor: 8.086
Authors: Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius Journal: Transplantation Date: 2015-11 Impact factor: 4.939